当前位置: X-MOL 学术J. Mass Spectrom. Adv. Clin. lab › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS
Journal of Mass Spectrometry and Advances in the Clinical Lab ( IF 2.1 ) Pub Date : 2017-12-16 , DOI: 10.1016/j.clinms.2017.12.002
M. Conti , T. Matulli Cavedagna , E. Ramazzotti , R. Mancini , L. Calza , M. Rinaldi , L. Badia , V. Guardigni , P. Viale , G. Verucchi

Background

Therapeutic drug monitoring (TDM) can be a useful tool in the clinical management of anti-hepatitis C virus (anti-HCV) drugs. Methods for the determination of various types of anti-HCV drugs in biological samples are, therefore, needed for clinical laboratories.

Objective

In this work, employing the LC–MS/MS approach, we aimed to develop a multiplexed method for identification of the following anti-HCV drugs: Ribavirin (RBV), Boceprevir (BOC), Telaprevir (TVR), Simeprevir (SIM), Daclatasvir (DAC), Sofosbuvir (SOF) and its metabolite GS 331007 (SOFM) in liquid plasma and in dried plasma spots (DPSs).

Method

A single-step extractive-deproteinization was employed for both liquid plasma and DPSs. Reverse-phase liquid chromatography coupled with MRM detection was developed for multiplexed drug detection and quantification.

Results

Sensitivities (expressed as LOQ) were 10 (±1.2), 10 (±4.9), 10 (±4.4), 10 (±4.4), 10 (±6.4), 10 (±3.4), 10 (±6.4) ng/ml for RBV, SOFM, SOF, DAC, BOC, TVR, and SIM, respectively; accuracy (expressed as BIAS%) was <10% for all drugs; reproducibility (intra- and inter-day CV%) was <10% for all drugs; dynamic range was 10–10,000 ng/ml for all drugs.

Conclusions

A novel, simple, rapid and robust LC–MS/MS multiplex assay for the TDM of various anti-HCV drugs that are currently in the clinic was successfully developed. Application to DPS samples enabled TDM to be used for outpatients as well.



中文翻译:

通过LC–MS / MS对抗病毒药物进行多重治疗药物监测(TDM)

背景

治疗药物监测(TDM)在抗丙型肝炎病毒(anti-HCV)药物的临床管理中可能是有用的工具。因此,临床实验室需要测定生物样品中各种类型的抗HCV药物的方法。

目的

在这项工作中,我们采用LC-MS / MS方法,旨在开发一种鉴定以下抗HCV药物的多重方法:利巴韦林(RBV),博西普韦(BOC),特拉普韦(TVR),西美普韦(SIM),达卡他韦(DAC),索非布韦(SOF)及其代谢产物GS 331007(SOFM)在血浆和干血浆斑点(DPS)中。

方法

血浆和DPS均采用一步萃取脱蛋白。开发了结合MRM检测的反相液相色谱用于多重药物检测和定量。

结果

灵敏度(以LOQ表示)为10(±1.2),10(±4.9),10(±4.4),10(±4.4),10(±6.4),10(±3.4),10(±6.4)ng / ml分别用于RBV,SOFM,SOF,DAC,BOC,TVR和SIM;所有药物的准确度(表示为BIAS%)均小于10%;所有药物的重现性(日内和日间CV%)均<10%;所有药物的动态范围为10–10,000 ng / ml。

结论

目前已成功开发出一种新颖,简单,快速且稳定的LC-MS / MS多重分析方法,用于多种抗HCV药物的TDM。将DDM应用于DPS样本后,TDM也可用于门诊病人。

更新日期:2017-12-16
down
wechat
bug